Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcγRI-calicheamicin immunoconjugate

le van Roon, J A G, Bijlsma, J, van de Winkel, J G J, Lafeber, F
Foilsithe 2005

FcγRIa–γ-chain complexes trigger antibody-dependent cell-mediated cytotoxicity (ADCC) in CD5(+) B cell/macrophage IIA1.6 cells

le Van Vugt, M J, Van Den Herik-Oudijk, I E, Van De Winkel, J G J
Foilsithe 1998

Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcγ RIIIa (CD16)

le KUMPEL, B M, DE HAAS, M, KOENE, H R, VAN DE WINKEL, J G J, GOODRICK, M J
Foilsithe 2003

Relevance of FcγRIIIa-158V-F polymorphism to recurrence of adult periodontitis in Japanese patients

le Sugita, N, Yamamoto, K, Kobayashi, T, Van Der Pol, W-L, Horigome, T, Yoshie, H, Van De Winkel, J G J, Hara, K
Foilsithe 1999

Meningococcal disease and polymorphism of FcγRIIa (CD32) in late complement component-deficient individuals

le Platonov, A E, Kuijper, E J, Vershinina, I V, Shipulin, A, Westerdaal, N, Fijen, C A P, Van DE Winkel, J G J
Foilsithe 1998

Fcγ receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms

le Manger, K, Repp, R, Jansen, M, Geisselbrecht, M, Wassmuth, R, Westerdaal, N, Pfahlberg, A, Manger, B, Kalden, J, van de Winkel, J G J
Foilsithe 2002

The role of Fcγ receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals

le Fijen, C A P, Bredius, R G M, Kuijper, E J, Out, T A, De Haas, M, De Wit, A P M, Daha, M R, Van De Winkel, J G J
Foilsithe 2000

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

le Repp, R, van Ojik, H H, Valerius, T, Groenewegen, G, Wieland, G, Oetzel, C, Stockmeyer, B, Becker, W, Eisenhut, M, Steininger, H, Deo, Y M, Blijham, G H, Kalden, J R, van de Winkel, J G J, Gramatzki, M
Foilsithe 2003